159 related articles for article (PubMed ID: 35089001)
1. Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma.
Chung C; Galvin R; Achenbach E; Dziadkowiec O; Sen S
Oncology (Williston Park); 2021 Dec; 35(12):794-803. PubMed ID: 35089001
[TBL] [Abstract][Full Text] [Related]
2. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
Botrus G; Kosirorek H; Sonbol MB; Kusne Y; Uson Junior PLS; Borad MJ; Ahn DH; Kasi PM; Drusbosky LM; Dada H; Surapaneni PK; Starr J; Ritter A; McMillan J; Wylie N; Mody K; Bekaii-Saab TS
Oncologist; 2021 Jul; 26(7):569-578. PubMed ID: 33555095
[TBL] [Abstract][Full Text] [Related]
4. Molecular Profiling Practices in Pancreatic Adenocarcinoma: Academic vs Community Physicians.
Chung C; Galvin R; Achenbach E; Dziadkowiec O; Sen S
Oncology (Williston Park); 2021 May; 35(5):244-248. PubMed ID: 33979117
[TBL] [Abstract][Full Text] [Related]
5. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
6. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA.
Kaseb AO; Sánchez NS; Sen S; Kelley RK; Tan B; Bocobo AG; Lim KH; Abdel-Wahab R; Uemura M; Pestana RC; Qiao W; Xiao L; Morris J; Amin HM; Hassan MM; Rashid A; Banks KC; Lanman RB; Talasaz A; Mills-Shaw KR; George B; Haque A; Raghav KPS; Wolff RA; Yao JC; Meric-Bernstam F; Ikeda S; Kurzrock R
Clin Cancer Res; 2019 Oct; 25(20):6107-6118. PubMed ID: 31363003
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
8. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma.
Affolter KE; Hellwig S; Nix DA; Bronner MP; Thomas A; Fuertes CL; Hamil CL; Garrido-Laguna I; Scaife CL; Mulvihill SJ; Underhill HR
Neoplasia; 2021 Sep; 23(9):859-869. PubMed ID: 34298235
[TBL] [Abstract][Full Text] [Related]
9. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma.
Schwaederlé MC; Patel SP; Husain H; Ikeda M; Lanman RB; Banks KC; Talasaz A; Bazhenova L; Kurzrock R
Clin Cancer Res; 2017 Sep; 23(17):5101-5111. PubMed ID: 28539465
[No Abstract] [Full Text] [Related]
10. Molecular profiling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application.
Sivapalan L; Kocher HM; Ross-Adams H; Chelala C
Pancreatology; 2021 Mar; 21(2):363-378. PubMed ID: 33451936
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma.
Kato S; Okamura R; Baumgartner JM; Patel H; Leichman L; Kelly K; Sicklick JK; Fanta PT; Lippman SM; Kurzrock R
Clin Cancer Res; 2018 Dec; 24(24):6248-6256. PubMed ID: 30348637
[TBL] [Abstract][Full Text] [Related]
13. Molecular Alterations Associated with DNA Repair in Pancreatic Adenocarcinoma Are Associated with Sites of Recurrence.
Ferguson MD; Dong L; Wan J; Deneve JL; Dickson PV; Behrman SW; Shibata D; Martin MG; Glazer ES
J Gastrointest Cancer; 2019 Jun; 50(2):285-291. PubMed ID: 29427136
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.
Strijker M; Soer EC; de Pastena M; Creemers A; Balduzzi A; Beagan JJ; Busch OR; van Delden OM; Halfwerk H; van Hooft JE; van Lienden KP; Marchegiani G; Meijer SL; van Noesel CJ; Reinten RJ; Roos E; Schokker S; Verheij J; van de Vijver MJ; Waasdorp C; Wilmink JW; Ylstra B; Besselink MG; Bijlsma MF; Dijk F; van Laarhoven HW
Int J Cancer; 2020 Mar; 146(5):1445-1456. PubMed ID: 31340061
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.
Groot VP; Mosier S; Javed AA; Teinor JA; Gemenetzis G; Ding D; Haley LM; Yu J; Burkhart RA; Hasanain A; Debeljak M; Kamiyama H; Narang A; Laheru DA; Zheng L; Lin MT; Gocke CD; Fishman EK; Hruban RH; Goggins MG; Molenaar IQ; Cameron JL; Weiss MJ; Velculescu VE; He J; Wolfgang CL; Eshleman JR
Clin Cancer Res; 2019 Aug; 25(16):4973-4984. PubMed ID: 31142500
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer.
Lin M; Alnaggar M; Liang S; Chen J; Xu K; Dong S; Du D; Niu L
Cell Physiol Biochem; 2018; 47(4):1556-1564. PubMed ID: 29940591
[TBL] [Abstract][Full Text] [Related]
17. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017.
Ding D; Javed AA; Cunningham D; Teinor J; Wright M; Javed ZN; Wilt C; Parish L; Hodgin M; Ryan A; Judkins C; McIntyre K; Klein R; Azad N; Lee V; Donehower R; De Jesus-Acosta A; Murphy A; Le DT; Shin EJ; Lennon AM; Khashab M; Singh V; Klein AP; Roberts NJ; Hacker-Prietz A; Manos L; Walsh C; Groshek L; Brown C; Yuan C; Blair AB; Groot V; Gemenetzis G; Yu J; Weiss MJ; Burkhart RA; Burns WR; He J; Cameron JL; Narang A; Zaheer A; Fishman EK; Thompson ED; Anders R; Hruban RH; Jaffee E; Wolfgang CL; Zheng L; Laheru DA
Cancer Lett; 2021 Jan; 497():221-228. PubMed ID: 33127389
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer.
Umemoto K; Sunakawa Y; Ueno M; Furukawa M; Mizuno N; Sudo K; Kawamoto Y; Kajiwara T; Ohtsubo K; Okano N; Matsuhashi N; Itoh S; Matsumoto T; Shimizu S; Otsuru T; Hasegawa H; Okuyama H; Ohama H; Moriwaki T; Ohta T; Odegaard JI; Nakamura Y; Bando H; Yoshino T; Ikeda M; Morizane C
Br J Cancer; 2023 Apr; 128(8):1603-1608. PubMed ID: 36782009
[TBL] [Abstract][Full Text] [Related]
19. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.
Pietrasz D; Pécuchet N; Garlan F; Didelot A; Dubreuil O; Doat S; Imbert-Bismut F; Karoui M; Vaillant JC; Taly V; Laurent-Puig P; Bachet JB
Clin Cancer Res; 2017 Jan; 23(1):116-123. PubMed ID: 27993964
[TBL] [Abstract][Full Text] [Related]
20. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
